Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
February 2023
Learn about a new study showing that patients taking rosuvastatin (CRESTOR, EZALLOR SPRINKLE) had a higher risk of proteinuria (abnormal levels of protein in the urine) and hematuria (blood in the urine) than those taking another statin, atorvastatin (LIPITOR).
November 2020
In his editor’s column, Dr. Michael Carome discusses U.S. Department of Justice charges brought against generic drug maker Teva for engaging in illegal price-gouging schemes for multiple prescription drugs.
February 2016
Statins have long been a mainstay of treatment for patients with high LDL (“bad” cholesterol) and cardiovascular disease. In this article, we explain why you should avoid combining a nonstatin cholesterol-lowering dug with a statin.
August 2013
A new study casts serious doubt on the usefulness of long-popular niacin products to treat or prevent cardiovascular disease.
November 2008
Despite the dangers of this combination--risk of severe muscle injury, rhabdomyolysis, which can lead to kidney failure or death--many clinicians continue to prescribe them together and cases of life-threatening adverse reactions from continue to be reported to the FDA. Patients taking simvastatin at a dose greater than 20 milligrams a day in combination with amiodarone should let their physician know that this combination puts them at high risk of muscle injury. There are other statins that do not appear to interact with amiodarone that are discussed.
March 2008
Find out why Worst Pills warned against the use of VYTORIN more than three years ago. Also, learn about new evidence showing that despite the fact that this drug lowers cholesterol, there is no evidence that it prevents heart attacks or strokes (though massive misleading advertising would have you believe otherwise).
July 2005
Further evidence that Crestor causes uniquely high rates of muscle and kidney damage
December 2004
We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
August 2004
We can think of no medical reason why you should be taking Caduet unless you are being treated satisfactorily with doses of amlodipine and atorvastatin that are available as Caduet. If you have not been tried on more effective drugs for high blood pressure such as diuretics or beta-blockers, amlodipine is a poor choice.
October 2003
Rosuvastatin (CRESTOR) became the sixth cholesterol lowering "statin" drug on the U.S. There is no medical reason for you to be taking rosuvastatin when there are three safer and more effective statins, in terms of reducing cardiovascular events, on the market.
December 2002
The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.
September 2002
Several new safety labeling changes have been required by the Food and Drug Administration (FDA) for the widely used anticoagulant drug warfarin (COUMADIN). These changes to the drug’s professional product labeling, or “package insert,” were made in May 2002. The article discusses the changes.
Login
Subscribe